<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of the causes of chronic diarrhea in children in resource-abundant settings</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of the causes of chronic diarrhea in children in resource-abundant settings</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of the causes of chronic diarrhea in children in resource-abundant settings</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin G Martin, MD, MPP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jay R Thiagarajah, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">B UK Li, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2619559018"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>While diarrhea is among the most common ailments affecting children, chronic diarrhea is relatively unusual in resource-abundant countries. It may be the manifestation of a broad group of disorders, ranging from an intolerance to a specific food (or food component) to an indication of a much broader multisystem condition.</p><p>This review will outline causes of chronic diarrhea in children that first present beyond early infancy (ie, after six months of age), organized by general pathophysiologic categories. A clinical approach to evaluating children with chronic diarrhea is presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5881.html" rel="external">"Approach to chronic diarrhea in children &gt;6 months in resource-abundant settings"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/117487.html" rel="external">"Approach to chronic diarrhea in neonates and young infants (&lt;6 months)"</a>.)</p><p></p><p class="headingAnchor" id="H4030889032"><span class="h1">DEFINITIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diarrhea</strong> – Objective definitions of diarrhea are based on stool weight or volume. However, because assessment of daily stool weights/volumes is difficult in the outpatient clinic setting, changes in the frequency and consistency of stool compared with baseline can also be used as a convenient gauge of diarrhea. Thus, one or both of the following measures can be used:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Stool weight – Daily stool weight greater than 250 g in children that weigh more than 10 kg is considered diarrhea. In young children (&lt;10 kg), stool in excess of 20 g/kg/day is abnormal.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Stool consistency – The Bristol stool chart is a useful tool to define stool consistencies [<a href="#rid1">1,2</a>]. Diarrheal stools typically correspond to types 6 and 7 on the Bristol stool chart [<a href="#rid3">3</a>] (or its slightly modified versions for children [<a href="#rid4">4</a>] or infants [<a href="#rid5">5</a>]). Low-volume loose stools are not a significant predictor of underlying disease in the absence of other symptoms such as weight loss, dehydration, or significant changes in biochemical/nutritional indicators.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic diarrhea</strong> – Chronic diarrhea is generally defined as diarrhea lasting greater than four weeks [<a href="#rid6">6</a>]. This timeline is selected to distinguish between the acute diarrheal episode, which tends to be self-limited, and more prolonged diarrheal disease that warrants further evaluation and possibly intervention.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Persistent diarrhea</strong> – The term persistent diarrhea is sometimes defined as diarrhea lasting longer than two weeks, but sometimes this term is used interchangeably with chronic diarrhea.</p><p></p><p class="headingAnchor" id="H3171741137"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Globally, the prevalence of diarrhea in children varies widely. Large-scale studies report that 3 to 20 percent of children under five years old have at least one episode per year, with an incidence of approximately 2.7 episodes per child-year in children younger than five years [<a href="#rid7">7</a>]. In resource-limited settings, chronic diarrhea is common and associated with significant mortality and morbidity.</p><p>In resource-abundant countries such as the United States, the prevalence of acute diarrhea is high, with 15 to 20 episodes per child-year in young children. However, the incidence of chronic diarrhea is substantially lower (less than 0.2 episodes per child-year) and is rarely severe, with less than 1 percent of episodes resulting in hospitalization [<a href="#rid8">8,9</a>].</p><p class="headingAnchor" id="H3437308742"><span class="h1">CATEGORIZATION OF DIARRHEA</span><span class="headingEndMark"> — </span>For clinical purposes, it is helpful to categorize chronic diarrhea by its proximate cause and other clinical characteristics, as outlined in the table  (<a class="graphic graphic_table graphicRef56837" href="/z/d/graphic/56837.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Physiologic (lactase nonpersistence)</p><p class="bulletIndent1"><span class="glyph">●</span>Infection-related</p><p class="bulletIndent1"><span class="glyph">●</span>Drug-induced</p><p class="bulletIndent1"><span class="glyph">●</span>Functional</p><p class="bulletIndent1"><span class="glyph">●</span>Immune-mediated</p><p class="bulletIndent1"><span class="glyph">●</span>Fat malabsorption</p><p class="bulletIndent1"><span class="glyph">●</span>Neuroendocrine disorders and tumors</p><p class="bulletIndent1"><span class="glyph">●</span>Congenital anomalies with bowel obstruction</p><p class="bulletIndent1"><span class="glyph">●</span>Other mechanisms</p><p></p><p>Other schemes classify diarrheas by the physiologic mechanism, ie, diet-induced (osmotic), electrolyte transport-related (secretory), motility-related, or inflammation-related. This framework is also important at certain steps in the evaluation process. These mechanisms are discussed in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/5860.html" rel="external">"Pathogenesis of acute diarrhea in children", section on 'Diarrhea classification'</a>.)</p><p class="headingAnchor" id="H560984596"><span class="h1">PHYSIOLOGIC</span></p><p class="headingAnchor" id="H2211366717"><span class="h2">Lactase nonpersistence</span><span class="headingEndMark"> — </span>Lactase nonpersistence (also called acquired lactose intolerance or hypolactasia) is a genetically determined phenotype that is particularly common in children of African, Hispanic, and Asian descent, typically developing in early to mid-childhood. Typical symptoms are abdominal pain, flatulence, nausea, bloating, and diarrhea after ingestion of milk or milk-containing products. Management is tailored to the symptoms and consists of dietary lactose restriction and/or taking a lactase enzyme preparation with lactose-containing foods. Children who avoid dairy products should be monitored and supplemented as needed to ensure adequate intake of calcium and vitamin D. (See  <a class="medical medical_review" href="/z/d/html/2542.html" rel="external">"Lactose intolerance and malabsorption: Clinical manifestations, diagnosis, and management"</a>.)</p><p class="headingAnchor" id="H2629104392"><span class="h1">INFECTION-RELATED CAUSES</span><span class="headingEndMark"> — </span>Diarrhea caused by bacterial or viral infections are often associated with constitutional symptoms of nausea, vomiting, fever, and, occasionally, dysentery. Most episodes of infectious diarrhea in an immunocompetent host resolve within two weeks since they either resolve spontaneously or are treatable with targeted antimicrobial therapies. (See  <a class="medical medical_review" href="/z/d/html/6456.html" rel="external">"Diagnostic approach to diarrhea in children in resource-abundant settings", section on 'Common conditions'</a>.)</p><p>Persistence of symptoms beyond two to four weeks may be related to underlying mucosal damage (postinfectious malabsorptive diarrhea including secondary lactose intolerance). If the infectious agent persists or recurs, an underlying primary or secondary immunodeficiency should be considered  (<a class="graphic graphic_table graphicRef56837" href="/z/d/graphic/56837.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H907581015"><span class="h2">Postinfectious malabsorptive diarrhea</span><span class="headingEndMark"> — </span>Postinfectious malabsorptive diarrhea is characterized by mucosal dysfunction that persists beyond four weeks after an acute enteric infection. This pattern is sometimes called postinfectious irritable bowel syndrome (IBS). In some cases, this is associated with residual mucosal inflammation and altered mucosal permeability and motility, which can cause diarrhea or upper gastrointestinal symptoms such as vomiting and dyspepsia [<a href="#rid10">10,11</a>]. As an example, one study in children who were followed for at least six months after acute bacterial gastroenteritis found a significantly higher risk (36 versus 11 percent of controls; relative risk 3.2) of developing abdominal pain that met criteria for IBS (87 percent) or dyspepsia (24 percent) [<a href="#rid12">12</a>].</p><p>More commonly, postinfectious diarrhea is caused by transient loss of lactase and other abnormalities that cause macro- and micronutrient malabsorption. This condition may persist for weeks or months after the infection resolves, particularly in malnourished children [<a href="#rid12">12,13</a>]. Lactose intolerance is the most common manifestation, but symptoms may include intolerance to a broad range of foods, and diarrheal symptoms may last for months.</p><p class="headingAnchor" id="H2068918983"><span class="h2">Persistent or recurrent infection</span></p><p class="headingAnchor" id="H2649618272"><span class="h3">With immunodeficiency</span><span class="headingEndMark"> — </span>If the infectious agent persists or recurs, an underlying primary or secondary immunodeficiency should be considered. These disorders are characterized by persistence of infection beyond the infectious period that would be expected in a normal host and/or unexplained recurrences of infectious diarrhea. These recurrent and prolonged infections are often caused by parasitic or viral agents and lead to severe and prolonged symptoms in a lymphopenic host.</p><p>Specific pathogens that tend to be involved in these cases include:</p><p class="bulletIndent1"><span class="glyph">●</span>Parasites – <em>Cryptosporidium</em>, <em>Isospora</em>, <em>Cyclospora</em>, and <em>Giardia lamblia</em>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Viruses – Rotavirus (with or without history of receiving the vaccine (see  <a class="medical medical_review" href="/z/d/html/2681.html" rel="external">"Clinical manifestations and diagnosis of rotavirus infection"</a>)), norovirus, astrovirus, adenovirus, and cytomegalovirus. These viruses tend to cause prolonged or non-self-resolving diarrhea in an immunocompromised host, in contrast with the self-resolving episodes in an immunocompetent host.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bacteria – <em>Clostridioides</em> <em>difficile</em>, <em>Salmonella</em>, <em>Campylobacter</em>, and Escherichia coli<em>.</em></p><p></p><p>T cell defects are associated with recurrent or persistent viral or parasitic infection, while B cell disorders are more often associated with bacterial infections. Important causes of primary and secondary immunodeficiency to consider include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary immunodeficiency</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cellular and humoral</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Severe combined immunodeficiency</p><p class="bulletIndent3"><span class="glyph">-</span>Regulatory T cell (Treg) dysfunction, including IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) and other disorders</p><p class="bulletIndent3"><span class="glyph">-</span>Wiskott-Aldrich syndrome</p><p></p><p class="bulletIndent2">(See  <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview"</a> and  <a class="medical medical_review" href="/z/d/html/3924.html" rel="external">"IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked"</a> and  <a class="medical medical_review" href="/z/d/html/3953.html" rel="external">"Wiskott-Aldrich syndrome"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Humoral</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Selective immunoglobulin A (IgA) deficiency</p><p class="bulletIndent3"><span class="glyph">-</span>Common variable immunodeficiency</p><p></p><p class="bulletIndent2">(See  <a class="medical medical_review" href="/z/d/html/3963.html" rel="external">"Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/16132.html" rel="external">"Common variable immunodeficiency in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary immunodeficiency</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Organ transplant recipients (due to immunosuppressants)</p><p class="bulletIndent2"><span class="glyph">•</span>Human immunodeficiency virus (HIV) infection (due to opportunistic infection in patients with active disease, or medication-induced)</p><p class="bulletIndent2"><span class="glyph">•</span>Malnutrition</p><p></p><p class="bulletIndent2">(See  <a class="medical medical_review" href="/z/d/html/3728.html" rel="external">"Evaluation of the patient with HIV and diarrhea"</a> and  <a class="medical medical_review" href="/z/d/html/5883.html" rel="external">"Malnutrition in children in resource-limited settings: Clinical assessment"</a> and  <a class="medical medical_review" href="/z/d/html/5878.html" rel="external">"Persistent diarrhea in children in resource-limited settings"</a>.)</p><p></p><p class="headingAnchor" id="H2804480513"><span class="h3">Without immunodeficiency</span><span class="headingEndMark"> — </span>Many children with recurrent gastrointestinal infections have no identifiable immunodeficiency. These children are typically asymptomatic between bouts of infections, whereas those with immunodeficiency are more likely to have persistent symptoms.</p><p>In an immunocompetent host, risk factors for recurrent or chronic infection include:</p><p class="bulletIndent1"><span class="glyph">●</span>Infection with <em>C. difficile</em>, which is notoriously difficult to eradicate. Similarly, children infected with <em>Salmonella</em> <em>typhi</em> frequently become carriers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Underlying inflammatory bowel disease (IBD), which predisposes the patient to recurrent infections such as cytomegalovirus and <em>C. difficile</em>.</p><p></p><p>(See  <a class="medical medical_review" href="/z/d/html/6048.html" rel="external">"<i>Clostridioides difficile</i> infection in children: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6050.html" rel="external">"<i>Clostridioides difficile</i> infection in children: Treatment and outcome"</a> and  <a class="medical medical_review" href="/z/d/html/2708.html" rel="external">"Enteric (typhoid and paratyphoid) fever: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2831859578"><span class="h1">DRUG-INDUCED CAUSES</span><span class="headingEndMark"> — </span>Drug-induced diarrhea is relatively common and may be caused by a wide variety of drugs  (<a class="graphic graphic_table graphicRef71449" href="/z/d/graphic/71449.html" rel="external">table 2</a>). Mechanisms may involve alteration of intestinal fluid, electrolyte and nutrient transport, or direct mucosal damage [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H1802574110"><span class="h2">Antibiotic-associated</span><span class="headingEndMark"> — </span>Antibacterial agents are particularly common causes of drug-induced diarrhea [<a href="#rid15">15</a>]. The risk of diarrhea depends on the type of antibiotic; it is particularly common with broad-spectrum antibiotics that are poorly absorbed, such as <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a>.</p><p class="bulletIndent1"><span class="glyph">●</span>Watery diarrhea following antibiotic use is generally benign, self-limiting, and requires no intervention. It usually results from the drug-induced microbial and metabolomic dysbiosis that eventually resolves [<a href="#rid16">16</a>]. Probiotics may help to prevent or shorten the course of antibiotic-associated diarrhea, based on limited information [<a href="#rid17">17-20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bloody diarrhea (indicating colitis) associated with antibiotic use is infrequent but problematic. It is caused by loss of normal bowel flora and subsequent <em>C. difficile</em> infection. Very rarely, this can progress to a fulminant colitis with multisystem failure [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/6048.html" rel="external">"<i>Clostridioides difficile</i> infection in children: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6050.html" rel="external">"<i>Clostridioides difficile</i> infection in children: Treatment and outcome"</a>.)</p><p></p><p class="headingAnchor" id="H1233667293"><span class="h2">Non-antibiotic-associated</span><span class="headingEndMark"> — </span>Diarrhea associated with nonantimicrobial drug therapies is common [<a href="#rid22">22</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drugs that do not injure the mucosa</strong> – For these drugs, diarrhea tends to start shortly after the drug is started and is often mild.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Laxatives (either prescribed or surreptitiously used) may result in an osmotic diarrhea in a dose-dependent manner.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Promotility agents such as <a class="drug drug_pediatric" data-topicid="12602" href="/z/d/drug information/12602.html" rel="external">metoclopramide</a>, macrolides, and <a class="drug drug_pediatric" data-topicid="13276" href="/z/d/drug information/13276.html" rel="external">erythromycin</a> shorten transit time and impair nutrient assimilation, leading to diarrhea.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Certain antidepressants (selective serotonin reuptake inhibitors) and anticholinergic agents reduce gastrointestinal motility, which may predispose to diarrhea due to bacterial overgrowth or by altering the microbiome [<a href="#rid23">23</a>]. The time course of onset may vary.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Drugs that impair assimilation of nutrients, such as <a class="drug drug_pediatric" data-topicid="131246" href="/z/d/drug information/131246.html" rel="external">orlistat</a> (a pancreatic lipase inhibitor), <a class="drug drug_pediatric" data-topicid="13198" href="/z/d/drug information/13198.html" rel="external">acarbose</a>, and <a class="drug drug_general" data-topicid="9538" href="/z/d/drug information/9538.html" rel="external">miglitol</a> (an alpha-glucosidase inhibitor), frequently result in diarrhea.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Certain antineoplastic agents (eg, tyrosine kinase inhibitors) can result in severe diarrhea without significant mucosal injury [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drugs that injure the mucosa</strong> – Drugs that are associated with significant alterations of the mucosa may take longer for clinical symptoms to appear.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antineoplastic drugs such as <a class="drug drug_pediatric" data-topicid="13314" href="/z/d/drug information/13314.html" rel="external">fluorouracil</a> and others are commonly associated with diarrhea that results from minor mucosal injury.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The purine synthesis inhibitor mycophenolic acid is commonly used in renal transplant patients. It frequently causes diarrhea, associated with leukopenia and with villous atrophy and apoptosis in the crypt.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other drugs, such as the angiotensin II receptor blocker <a class="drug drug_pediatric" data-topicid="16034" href="/z/d/drug information/16034.html" rel="external">olmesartan</a>, are associated with a sprue-like enteropathy that results in chronic diarrhea that can be severe [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/z/d/html/3816.html" rel="external">"Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers", section on 'ARBs'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Microscopic colitis is a chronic inflammatory colitis that is seen almost exclusively in adults but has been reported in children. Risk factors include chronic use of nonsteroidal antiinflammatory drugs and proton pump inhibitors, among other drugs. (See  <a class="medical medical_review" href="/z/d/html/4071.html" rel="external">"Microscopic (lymphocytic and collagenous) colitis: Clinical manifestations, diagnosis, and management", section on 'Medications'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Numerous immunotherapies are specifically associated with an immune-related adverse effect that includes diarrhea. For instance, <a class="drug drug_pediatric" data-topicid="116880" href="/z/d/drug information/116880.html" rel="external">ipilimumab</a> (CTLA-4) and anti-PD-1 antibodies may result in a clinical course resembling both celiac disease and inflammatory bowel disease (IBD) [<a href="#rid26">26</a>].</p><p></p><p class="headingAnchor" id="H3644833321"><span class="h1">FUNCTIONAL DIARRHEAL DISORDERS</span></p><p class="headingAnchor" id="H3146225821"><span class="h2">Functional diarrhea in young children</span><span class="headingEndMark"> — </span>Functional diarrhea in young children (sometimes known as "toddler's diarrhea") refers to chronic diarrhea or loose stools in an otherwise healthy young child with no underlying disease. This disorder can present as early as six months of age and is characterized by four or more large, painless stools per day, progressing in consistency from semi-solid in the morning to loose as the day progresses. Stools can contain undigested food and be watery. Intercurrent illness and stressors (excitement) may be triggers for exacerbations that last more than four weeks. The symptoms usually resolve by four to five years of age.</p><p>This disorder is thought to be common, with survey studies indicating prevalence among young children between 0.9 and 6.4 percent [<a href="#rid27">27,28</a>]. However, in many cases, the stools are simply loose and do not meet the formal definition of diarrhea in terms of volume, frequency, or severity (ie, no predisposition to dehydration or weight loss), so the true prevalence of diarrhea caused by this mechanism may be lower.</p><p>In some children, the symptoms appear to be associated with the excessive use of fructose- or sorbitol-based juices or diets high in sugar or other carbohydrates. In these cases, the severity of the diarrhea is dose-dependent and improves with restricting the intake of carbohydrate-rich food or beverages. However, in other cases, the diarrhea or loose stools continue regardless of dietary restriction. If the toddler is growing well and is otherwise healthy, no diagnostic testing or elimination diet is recommended. The parent/caregiver(s) can be reassured that the symptoms will likely have a benign course and eventually resolve by age five.</p><p class="headingAnchor" id="H4006065808"><span class="h2">Diarrhea-predominant irritable bowel syndrome</span><span class="headingEndMark"> — </span>Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent abdominal pain and a change of stool form or frequency. It is more common in adolescents compared with younger age groups. The estimated prevalence of IBS is between 1 and 3 percent among children in the United States [<a href="#rid29">29</a>]. As with other functional disorders, the diagnosis is based on symptoms and excluding other disorders. (See  <a class="medical medical_review" href="/z/d/html/112.html" rel="external">"Functional abdominal pain in children and adolescents: Management in primary care"</a> and  <a class="medical medical_review" href="/z/d/html/2630.html" rel="external">"Clinical manifestations and diagnosis of irritable bowel syndrome in adults"</a>.)</p><p>A subset of IBS is associated with mild diarrhea, known as diarrhea-predominant IBS or IBS-D. IBS-D can be seen at most ages, but it is more prevalent in adolescent females and generally is associated with low-volume loose stools, abdominal pain, urgency, and sensation of incomplete evacuation.</p><p class="headingAnchor" id="H3144675453"><span class="h1">IMMUNE-MEDIATED CAUSES</span><span class="headingEndMark"> — </span>Immunologic mechanisms are responsible for several causes of chronic diarrhea, including some common disorders  (<a class="graphic graphic_table graphicRef56837" href="/z/d/graphic/56837.html" rel="external">table 1</a>):</p><p class="headingAnchor" id="H2685462201"><span class="h2">Common causes</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Celiac disease</strong> – Celiac disease is relatively common and may present at any age with failure to thrive, diarrhea, or, occasionally, with constipation. Many cases are now detected by testing asymptomatic children who have risk factors for celiac disease (eg, children who have type 1 diabetes or first-degree relatives with celiac disease). Celiac disease is a gluten-sensitive enteropathy that leads to an immune-mediated enteropathy that reduces the nutrient-absorptive capacity of the small bowel. A lifelong strict elimination of dietary gluten is required and is effective in the majority of cases. (See  <a class="medical medical_review" href="/z/d/html/5899.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in children"</a> and  <a class="medical medical_review" href="/z/d/html/100553.html" rel="external">"Diagnosis of celiac disease in children"</a> and  <a class="medical medical_review" href="/z/d/html/5907.html" rel="external">"Management of celiac disease in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inflammatory bowel disease (IBD)</strong> – IBD (ulcerative colitis or Crohn disease) typically presents with a prolonged history of diarrhea, generally associated with mucous and, occasionally, blood. While the peak incidence of IBD is during adolescence or mid-adulthood, it can occur at any age. When IBD begins in infancy, it tends to have more protracted course that is less responsive to medical therapy and is more likely to result from a genetic basis. (See  <a class="medical medical_review" href="/z/d/html/5879.html" rel="external">"Clinical presentation and diagnosis of inflammatory bowel disease in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Food protein-induced allergic proctocolitis</strong> – Food protein-induced allergic proctocolitis, sometimes known as food-protein intolerance, is a common cause of diarrhea or loose stools in infants. It usually resolves before one year of age but can rarely extend to toddlers and school-aged children. The most common food triggers are cow's milk, egg, or soy in the diet. (See  <a class="medical medical_review" href="/z/d/html/5897.html" rel="external">"Food protein-induced allergic proctocolitis of infancy"</a>.)</p><p></p><p class="headingAnchor" id="H1150485987"><span class="h2">Uncommon causes</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Food protein-induced enterocolitis</strong> – Food protein-induced enterocolitis is a non-IgE-mediated food hypersensitivity syndrome that presents during infancy and typically resolves by three years of age. It is characterized by acute onset of profuse, repetitive vomiting with or without diarrhea following exposure to the offending food antigen. This leads to dehydration and lethargy. Chronic symptoms may include watery diarrhea with intermittent vomiting, leading to weight loss, failure to thrive, dehydration, and metabolic derangements ’ [<a href="#rid30">30</a>]. The diagnosis of food protein-induced enterocolitis is based upon the history, constellation of typical clinical symptoms with clinical improvement following elimination of the suspected causal protein, exclusion of other etiologies, and, if necessary, results of an oral food challenge. (See  <a class="medical medical_review" href="/z/d/html/16528.html" rel="external">"Food protein-induced enterocolitis syndrome (FPIES)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eosinophilic gastroenteritis</strong> – Eosinophilic gastroenteritis is a relatively rare disorder whose pathogenesis is poorly understood, but most children have elevated serum IgE levels. These patients have a propensity for protein-losing enteropathy and significant asthma and eczema. While a definitive dietary allergen is not usually identified, many patients respond to an elimination diet or elemental diet but frequently require steroid management. (See  <a class="medical medical_review" href="/z/d/html/2536.html" rel="external">"Eosinophilic gastrointestinal diseases"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microscopic colitis</strong> – This disorder occurs primarily in adults and presents with watery, nonbloody diarrhea. Risk factors include chronic use of nonsteroidal antiinflammatory drugs and proton pump inhibitors (see <a class="local">'Non-antibiotic-associated'</a> above). It is characterized by grossly normal-appearing colonic mucosa, with histologic evidence of either a lymphocytic or collagenous colitis [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/4071.html" rel="external">"Microscopic (lymphocytic and collagenous) colitis: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Polyglandular autoimmune syndrome</strong> – This is an autosomal recessive disorder that results in the clinical triad of mucocutaneous candidiasis, hypoparathyroidism, and adrenal failure. Type 1 tends to present during childhood and is rare. Affected patients can also develop either episodic or persistent generalized malabsorptive diarrhea with loss of enteroendocrine cells and poor weight gain [<a href="#rid32">32</a>]. Severe malabsorptive diarrhea may be the first clinical manifestation of this disorder. (See  <a class="medical medical_review" href="/z/d/html/5813.html" rel="external">"Causes of primary adrenal insufficiency in children", section on 'Autoimmune disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cutaneous and systemic forms of mastocytosis</strong> – The majority of patients with this disorder have cutaneous lesions, and many have lymphadenopathy, splenomegaly, gastrointestinal ulcers, and hepatitis. Diarrhea is a common manifestation in either cutaneous or systemic mastocytosis, mediated by histamine release. This may be triggered by certain medicines (eg nonsteroidal antiinflammatory drugs and some antibiotics), infections, or spicy foods. (See  <a class="medical medical_review" href="/z/d/html/103161.html" rel="external">"Mastocytosis (cutaneous and systemic) in children: Epidemiology, clinical manifestations, evaluation, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H1822608890"><span class="h1">FAT MALABSORPTION</span><span class="headingEndMark"> — </span>Fat malabsorption may be caused by several different mechanisms  (<a class="graphic graphic_table graphicRef56837" href="/z/d/graphic/56837.html" rel="external">table 1</a>):</p><p class="headingAnchor" id="H131684468"><span class="h2">Pancreatic exocrine insufficiency</span><span class="headingEndMark"> — </span>Deficiency of pancreatic lipase leads to maldigestion of fat due to lack of micellization in the bowel lumen. Cystic fibrosis is the most common cause of pancreatic exocrine insufficiency. Other causes include Shwachman-Diamond syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F260400&amp;token=tEpDslnpc0F0kICl%2Fz7sFVotXPSmMDaW2EHangYam63RhjFz3xVE8oB%2F4VGTuqZg&amp;TOPIC_ID=5877" target="_blank">MIM #260400</a>; associated with bone marrow failure and skeletal abnormalities), some cases of advanced chronic pancreatitis, and four rare disorders (Pearson syndrome [<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F557000&amp;token=87jLzclRwWxNoI%2BQq5Gg76nClTFje4YId1FBT3WcPShFzW5Jifys5hqKU2yoE5mi&amp;TOPIC_ID=5877" target="_blank">MIM #557000</a>], Johanson-Blizzard syndrome [<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F243800&amp;token=87jLzclRwWxNoI%2BQq5Gg7x%2BDZ813LGr8Whhf8F7u2IwNYOBVhdZtsT7859AcFrAF&amp;TOPIC_ID=5877" target="_blank">MIM #243800</a>], pancreatic lipase deficiency [<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F614338&amp;token=87jLzclRwWxNoI%2BQq5Gg7x4sk5TZSY0i0yxojYafAsU8BFxHdtaFZSJlhd%2BVt7As&amp;TOPIC_ID=5877" target="_blank">MIM #614338</a>], and colipase deficiency [also <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F614338&amp;token=87jLzclRwWxNoI%2BQq5Gg7x4sk5TZSY0i0yxojYafAsU8BFxHdtaFZSJlhd%2BVt7As&amp;TOPIC_ID=5877" target="_blank">MIM #614338</a>]). (See  <a class="medical medical_review" href="/z/d/html/5885.html" rel="external">"Cystic fibrosis: Assessment and management of pancreatic insufficiency"</a> and  <a class="medical medical_review" href="/z/d/html/5914.html" rel="external">"Shwachman-Diamond syndrome"</a>.)</p><p class="headingAnchor" id="H199370269"><span class="h2">Bile acid insufficiency</span><span class="headingEndMark"> — </span>Deficiency of bile acids in the intestinal lumen also leads to maldigestion of fat. This may be seen in patients with bile acid malabsorption due to resection or inflammation of the terminal ileum, which depletes the bile acid pool. Crohn disease is a common cause of terminal ileal disease. Bile acid insufficiency also may be caused by bile salt deconjugation, which is one of several mechanisms that can cause diarrhea in patients with small intestine bacterial overgrowth. (See <a class="local">'Small intestinal bacterial overgrowth'</a> below.)</p><p class="headingAnchor" id="H145865757"><span class="h2">Mucosal malabsorption</span><span class="headingEndMark"> — </span>Extensive mucosal disease or resection of the small bowel can lead to fat malabsorption; this may occur in patients with short bowel syndrome or severe and diffuse small intestinal Crohn disease. (See  <a class="medical medical_review" href="/z/d/html/4770.html" rel="external">"Pathophysiology of short bowel syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/5886.html" rel="external">"Chronic complications of short bowel syndrome in children", section on 'Nutritional complications'</a>.)</p><p class="headingAnchor" id="H155577551"><span class="h1">NEUROENDOCRINE TUMORS AND RELATED DISORDERS</span><span class="headingEndMark"> — </span>Neuroendocrine tumors are rare causes of chronic diarrhea in children  (<a class="graphic graphic_table graphicRef56837" href="/z/d/graphic/56837.html" rel="external">table 1</a>). When they do occur, they usually are associated with one of the following disorders:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurofibromatosis</strong> – Neurofibromatosis is relatively common and is suspected in children with multiple café-au-lait macules and neurofibromas. A small subset develop tumors that can result in secretory diarrhea, including gastrointestinal stromal tumors, carcinoid tumors, pheochromocytoma, gastrinomas, or somatostatinomas. (See  <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis", section on 'Gastrointestinal stromal tumors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuroblastomas and ganglioneuroblastoma</strong> – Relatively well-differentiated forms of neuroblastomas may be associated with severe secretory diarrhea that is frequently associated with elevated levels of vasoactive intestinal polypeptide. (See  <a class="medical medical_review" href="/z/d/html/5187.html" rel="external">"Clinical presentation, diagnosis, and staging evaluation of neuroblastoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multiple endocrine neoplasia type 2b</strong> – This is an exceedingly rare autosomal dominant disorder characterized by ganglioneuromas, medullary thyroid cancer, and pheochromocytoma. The ganglioneuromas are associated with severe secretory diarrhea and flushing. (See  <a class="medical medical_review" href="/z/d/html/7870.html" rel="external">"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2"</a>.)</p><p></p><p class="headingAnchor" id="H4038059965"><span class="h1">CONGENITAL CONDITIONS ASSOCIATED WITH BOWEL OBSTRUCTION</span><span class="headingEndMark"> — </span>Partial bowel obstruction may present with chronic or intermittent diarrhea. The underlying mechanism probably includes dysmotility with small intestine bacterial overgrowth, which in turn causes mucosal injury and malabsorption and/or deconjugation of bile acids with maldigestion. (See <a class="local">'Small intestinal bacterial overgrowth'</a> below and <a class="local">'Other'</a> below.)</p><p>Congenital conditions that predispose to this complication include  (<a class="graphic graphic_table graphicRef56837" href="/z/d/graphic/56837.html" rel="external">table 1</a>):</p><p class="headingAnchor" id="H2902771032"><span class="h2">Chronic intestinal pseudo-obstruction</span><span class="headingEndMark"> — </span>Chronic intestinal pseudo-obstruction is a rare disorder that presents during early infancy with severe constipation, abdominal distention, and dilated bowels, with intolerance to luminal feeds that usually requires parenteral nutrition. This disorder can be classified as myogenic (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F155310&amp;token=tEpDslnpc0F0kICl%2Fz7sFdq7KW313yBvat27CnEqDw8sT81P1wwdAzhnrrh%2FdAdg&amp;TOPIC_ID=5877" target="_blank">MIM #155310</a>) or neurogenic (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F243180&amp;token=tEpDslnpc0F0kICl%2Fz7sFZDxK7ki9TNJyVXNO7kDVoOvJYCIMMhJK3jwMzEWyfvu&amp;TOPIC_ID=5877" target="_blank">MIM #243180</a>) with specific characteristics. Both forms are associated with severe, recurrent bouts of small bowel bacterial overgrowth that may be associated with episodic worsening of abdominal distension and diarrhea. (See  <a class="medical medical_review" href="/z/d/html/2639.html" rel="external">"Chronic intestinal pseudo-obstruction: Etiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H731966715"><span class="h2">Hirschsprung disease</span><span class="headingEndMark"> — </span>Hirschsprung disease is relatively common and results from failure of neural crest cell migration that leads to an absence of enteric ganglion from the rectum extending proximally. The resulting aganglionic segment of the colon fails to relax, causing a functional obstruction. Hirschsprung disease may lead to an associated enterocolitis with fever, abdominal distention, explosive diarrhea, and vomiting that can progress to toxic megacolon. Hirschsprung-associated enterocolitis can occur even after surgery for Hirschsprung disease and in children &gt;6 months old. (See  <a class="medical medical_review" href="/z/d/html/5903.html" rel="external">"Congenital aganglionic megacolon (Hirschsprung disease)"</a> and  <a class="medical medical_review" href="/z/d/html/5891.html" rel="external">"Emergency complications of Hirschsprung disease", section on 'Enterocolitis'</a>.)</p><p class="headingAnchor" id="H3109229063"><span class="h2">Intestinal malrotation with intermittent volvulus</span><span class="headingEndMark"> — </span>Intestinal malrotation is a relatively common anatomical abnormality. In some cases, it leads to volvulus that usually presents early in life with sudden-onset emesis, rectal bleeding, and circulatory shock. An intermittent form of volvulus has also been described, which presents with episodic emesis and malabsorptive diarrhea.</p><p class="headingAnchor" id="H789480689"><span class="h1">OTHER MECHANISMS</span><span class="headingEndMark"> — </span>Other causes of chronic diarrhea include  (<a class="graphic graphic_table graphicRef56837" href="/z/d/graphic/56837.html" rel="external">table 1</a>):</p><p class="headingAnchor" id="H3561187269"><span class="h2">Small intestinal bacterial overgrowth</span><span class="headingEndMark"> — </span>Small intestinal bacterial overgrowth (SIBO) is a condition in which the small bowel is colonized by excessive aerobic and anaerobic microbes that are normally present in the colon. This can cause diarrhea by direct mucosal injury, production of enterotoxins, and/or maldigestion because of bile salt deconjugation. Typical symptoms include bloating, flatulence, abdominal discomfort, or watery diarrhea. The incidence of SIBO increases with age. Several disorders predispose to SIBO by altering mucosal defenses. (See  <a class="medical medical_review" href="/z/d/html/4776.html" rel="external">"Small intestinal bacterial overgrowth: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H2388438383"><span class="h2">Congenital diarrheas and enteropathies</span><span class="headingEndMark"> — </span>Chronic diarrhea that presents in early infancy (&lt;6 months) has a unique set of causes, as outlined in the table  (<a class="graphic graphic_table graphicRef118302" href="/z/d/graphic/118302.html" rel="external">table 3</a>). These include congenital diarrheas and enteropathies, which are primarily inherited defects of epithelial function and typically present in the neonatal period. (See  <a class="medical medical_review" href="/z/d/html/117487.html" rel="external">"Approach to chronic diarrhea in neonates and young infants (&lt;6 months)"</a>.)</p><p class="headingAnchor" id="H1327010910"><span class="h2">Other</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bile acid malabsorption</strong> – Bile acids secreted into the intestinal lumen are normally reabsorbed in the terminal ileum. In patients with ileal disease or resection, or those with genetic defects in bile acid transport (eg, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F613291&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz4GgeeiX%2By4mdW929mKX3v%2B&amp;TOPIC_ID=5877" target="_blank">MIM #613291</a>), the malabsorbed bile acids enter the colon, where they can cause a secretory diarrhea (this is sometimes called cholerheic diarrhea). Treatment with <a class="drug drug_pediatric" data-topicid="13152" href="/z/d/drug information/13152.html" rel="external">cholestyramine</a> prevents this process by sequestering bile acids. However, cholestyramine must be used judiciously since some patients may also have bile acid deficiency; in these patients, cholestyramine may bind the remaining bile salts necessary for fat and fat-soluble vitamin absorption, thereby creating additional unwanted nutritional complications.</p><p></p><p class="bulletIndent1">Bile acid malabsorption diarrhea occasionally occurs after cholecystectomy. (See  <a class="medical medical_review" href="/z/d/html/2591.html" rel="external">"Approach to the adult with chronic diarrhea in resource-abundant settings", section on 'Post-cholecystectomy diarrhea'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protein-losing enteropathies</strong> – Protein-losing enteropathy is classically seen in the setting of severe mucosal inflammation and permeability, which may occur in erosive gastrointestinal diseases (inflammatory bowel disease [IBD] or <em>C. difficile</em> infection) or nonerosive disease (celiac disease or eosinophilic gastroenteritis)  (<a class="graphic graphic_table graphicRef53419" href="/z/d/graphic/53419.html" rel="external">table 4</a>). Occasionally, it may be caused by impaired lymphatic drainage or after the Fontan procedure for congenital heart disease. (See  <a class="medical medical_review" href="/z/d/html/95232.html" rel="external">"Management of complications in patients with Fontan circulation", section on 'Protein-losing enteropathy'</a>.)</p><p></p><p class="bulletIndent1">While chronic diarrhea is common in these conditions, significant protein-losing enteropathy may be present even in the absence of diarrhea. Other common features include peripheral edema, hypoalbuminemia, hypogammaglobulinemia, and, sometimes, lymphopenia. (See  <a class="medical medical_review" href="/z/d/html/4769.html" rel="external">"Protein-losing gastroenteropathy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factitious diarrhea</strong> – Factitious diarrhea may be due to a self-induced true increase in stool volume (eg, from surreptitious laxative abuse) or the creation of an apparent increase in stool volume by the addition of various substances (eg, urine, water) to the stool with the intention of misleading the health professional. Diagnosing factitious diarrhea is often difficult and requires alertness to this possibility and exclusion of other diseases and may be aided by specific testing (eg, stool osmolality or a laxative screen). (See  <a class="medical medical_review" href="/z/d/html/2628.html" rel="external">"Factitious diarrhea: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p class="bulletIndent1">In children, factitious diarrhea may be contrived by the caregiver in a form of medical child abuse. (See  <a class="medical medical_review" href="/z/d/html/6608.html" rel="external">"Medical child abuse (Munchausen syndrome by proxy)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vasculitis</strong> – Vasculitides including polyarteritis nodosa or Behçet syndrome may be associated with chronic diarrhea. These disorders usually can be identified by their constitutional symptoms or signs, skin lesions, laboratory evidence of inflammation, and bloody diarrhea. (See  <a class="medical medical_review" href="/z/d/html/6430.html" rel="external">"Vasculitis in children: Evaluation overview"</a>.)</p><p></p><p class="headingAnchor" id="H1973401231"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/127092.html" rel="external">"Society guideline links: Chronic diarrhea"</a>.)</p><p class="headingAnchor" id="H1039092752"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> – Chronic diarrhea can be defined as daily stool weight of greater than 250 g in children that weigh more than 10 kg and greater than 20 g/kg/day in children that weigh less than 10 kg for longer than four weeks. In the outpatient clinical setting, changes in the frequency and consistency of stool compared with baseline can also be used as a convenient gauge of diarrhea. The Bristol stool chart is a reliable tool to define stool consistencies; diarrheal stools typically correspond to Bristol types 6 and 7. (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes of chronic diarrhea in children</strong> – For clinical purposes, it is helpful to categorize chronic diarrhea by triggers and other clinical characteristics  (<a class="graphic graphic_table graphicRef56837" href="/z/d/graphic/56837.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Common causes</strong> – Relatively common causes of chronic diarrhea in children include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Physiologic lactase nonpersistence (see <a class="local">'Lactase nonpersistence'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Gastrointestinal infections (especially postinfectious processes) (see <a class="local">'Infection-related causes'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Drug-induced diarrhea, eg, due to certain antibiotics, laxatives, and antineoplastic medications  (<a class="graphic graphic_table graphicRef71449" href="/z/d/graphic/71449.html" rel="external">table 2</a>) (see <a class="local">'Drug-induced causes'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Functional disorders such as toddler's diarrhea and diarrhea-predominant irritable bowel syndrome (IBS-D) (see <a class="local">'Functional diarrheal disorders'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Immune-mediated causes such as celiac disease and inflammatory bowel disease (IBD) (see <a class="local">'Immune-mediated causes'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Less common causes</strong> – Less common mechanisms for chronic diarrhea include other immune-mediated disorders, pancreatic exocrine insufficiency, and partial bowel obstruction due to chronic intestinal pseudo-obstruction or other congenital conditions. (See <a class="local">'Fat malabsorption'</a> above and <a class="local">'Congenital conditions associated with bowel obstruction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Causes in young infants</strong> – Chronic diarrhea that presents in early infancy (&lt;6 months) has a unique set of causes, which include anatomic defects and heritable disorders of immune regulation, macronutrient digestion, mucosal barrier function, and transport  (<a class="graphic graphic_table graphicRef118302" href="/z/d/graphic/118302.html" rel="external">table 3</a>); these disorders are discussed in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/117487.html" rel="external">"Approach to chronic diarrhea in neonates and young infants (&lt;6 months)"</a>.)</p><p></p><p class="headingAnchor" id="H3186775610"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Richard Kellermayer, MD, PhD, and Robert Shulman, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. Gastroenterology 2016; 150:1393.</a></li><li><a class="nounderline abstract_t">Chumpitazi BP, Self MM, Czyzewski DI, et al. Bristol Stool Form Scale reliability and agreement decreases when determining Rome III stool form designations. Neurogastroenterol Motil 2016; 28:443.</a></li><li><a class="nounderline abstract_t">Stotzer PO, Abrahamsson H, Bajor A, et al. Are the definitions for chronic diarrhoea adequate? Evaluation of two different definitions in patients with chronic diarrhoea. United European Gastroenterol J 2015; 3:381.</a></li><li><a class="nounderline abstract_t">Lane MM, Czyzewski DI, Chumpitazi BP, Shulman RJ. Reliability and validity of a modified Bristol Stool Form Scale for children. J Pediatr 2011; 159:437.</a></li><li><a class="nounderline abstract_t">Wegh CAM, Hermes GDA, Schoterman MHC, et al. The Modified Bristol Stool Form Scale: A Reliable and Valid Tool to Score Stool Consistency in Dutch (Non)Toilet-trained Toddlers. J Pediatr Gastroenterol Nutr 2021; 73:210.</a></li><li><a class="nounderline abstract_t">Schiller LR, Pardi DS, Sellin JH. Chronic Diarrhea: Diagnosis and Management. Clin Gastroenterol Hepatol 2017; 15:182.</a></li><li><a class="nounderline abstract_t">Walker CL, Rudan I, Liu L, et al. Global burden of childhood pneumonia and diarrhoea. Lancet 2013; 381:1405.</a></li><li><a class="nounderline abstract_t">Malek MA, Curns AT, Holman RC, et al. Diarrhea- and rotavirus-associated hospitalizations among children less than 5 years of age: United States, 1997 and 2000. Pediatrics 2006; 117:1887.</a></li><li><a class="nounderline abstract_t">Vernacchio L, Vezina RM, Mitchell AA, et al. Characteristics of persistent diarrhea in a community-based cohort of young US children. J Pediatr Gastroenterol Nutr 2006; 43:52.</a></li><li><a class="nounderline abstract_t">Verdu EF, Riddle MS. Chronic gastrointestinal consequences of acute infectious diarrhea: evolving concepts in epidemiology and pathogenesis. Am J Gastroenterol 2012; 107:981.</a></li><li><a class="nounderline abstract_t">DuPont AW. Postinfectious irritable bowel syndrome. Clin Infect Dis 2008; 46:594.</a></li><li><a class="nounderline abstract_t">Saps M, Pensabene L, Di Martino L, et al. Post-infectious functional gastrointestinal disorders in children. J Pediatr 2008; 152:812.</a></li><li><a class="nounderline abstract_t">MacGillivray S, Fahey T, McGuire W. Lactose avoidance for young children with acute diarrhoea. Cochrane Database Syst Rev 2013; :CD005433.</a></li><li><a class="nounderline abstract_t">Chassany O, Michaux A, Bergmann JF. Drug-induced diarrhoea. Drug Saf 2000; 22:53.</a></li><li><a class="nounderline abstract_t">Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002; 346:334.</a></li><li><a class="nounderline abstract_t">Suez J, Zmora N, Zilberman-Schapira G, et al. Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT. Cell 2018; 174:1406.</a></li><li><a class="nounderline abstract_t">Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 2012; 307:1959.</a></li><li><a class="nounderline abstract_t">Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2005; 21:583.</a></li><li><a class="nounderline abstract_t">Guo Q, Goldenberg JZ, Humphrey C, et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2019; 4:CD004827.</a></li><li><a class="nounderline abstract_t">Lukasik J, Dierikx T, Besseling-van der Vaart I, et al. Multispecies Probiotic for the Prevention of Antibiotic-Associated Diarrhea in Children: A Randomized Clinical Trial. JAMA Pediatr 2022; 176:860.</a></li><li><a class="nounderline abstract_t">McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018; 66:e1.</a></li><li><a class="nounderline abstract_t">Philip NA, Ahmed N, Pitchumoni CS. Spectrum of Drug-induced Chronic Diarrhea. J Clin Gastroenterol 2017; 51:111.</a></li><li><a class="nounderline abstract_t">Maier L, Pruteanu M, Kuhn M, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018; 555:623.</a></li><li><a class="nounderline abstract_t">Duan T, Cil O, Thiagarajah JR, Verkman AS. Intestinal epithelial potassium channels and CFTR chloride channels activated in ErbB tyrosine kinase inhibitor diarrhea. JCI Insight 2019; 4.</a></li><li><a class="nounderline abstract_t">Rubio-Tapia A, Herman ML, Ludvigsson JF, et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc 2012; 87:732.</a></li><li><a class="nounderline abstract_t">Cramer P, Bresalier RS. Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors. Curr Gastroenterol Rep 2017; 19:3.</a></li><li><a class="nounderline abstract_t">van Tilburg MA, Hyman PE, Walker L, et al. Prevalence of functional gastrointestinal disorders in infants and toddlers. J Pediatr 2015; 166:684.</a></li><li><a class="nounderline abstract_t">Benninga MA, Faure C, Hyman PE, et al. Childhood Functional Gastrointestinal Disorders: Neonate/Toddler. Gastroenterology 2016.</a></li><li><a class="nounderline abstract_t">Hyams JS, Di Lorenzo C, Saps M, et al. Functional Disorders: Children and Adolescents. Gastroenterology 2016.</a></li><li><a class="nounderline abstract_t">Nowak-Węgrzyn A, Chehade M, Groetch ME, et al. International consensus guidelines for the diagnosis and management of food protein-induced enterocolitis syndrome: Executive summary-Workgroup Report of the Adverse Reactions to Foods Committee, American Academy of Allergy, Asthma &amp; Immunology. J Allergy Clin Immunol 2017; 139:1111.</a></li><li><a class="nounderline abstract_t">Beaugerie L, Luboinski J, Brousse N, et al. Drug induced lymphocytic colitis. Gut 1994; 35:426.</a></li><li><a class="nounderline abstract_t">Husebye ES, Anderson MS, Kämpe O. Autoimmune Polyendocrine Syndromes. N Engl J Med 2018; 378:1132.</a></li></ol></div><div id="topicVersionRevision">Topic 5877 Version 43.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27144627" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Bowel Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26690980" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Bristol Stool Form Scale reliability and agreement decreases when determining Rome III stool form designations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26279847" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Are the definitions for chronic diarrhoea adequate? Evaluation of two different definitions in patients with chronic diarrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21489557" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Reliability and validity of a modified Bristol Stool Form Scale for children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34402810" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The Modified Bristol Stool Form Scale: A Reliable and Valid Tool to Score Stool Consistency in Dutch (Non)Toilet-trained Toddlers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27496381" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Chronic Diarrhea: Diagnosis and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23582727" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Global burden of childhood pneumonia and diarrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16740827" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Diarrhea- and rotavirus-associated hospitalizations among children less than 5 years of age: United States, 1997 and 2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16819377" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Characteristics of persistent diarrhea in a community-based cohort of young US children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22508147" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Chronic gastrointestinal consequences of acute infectious diarrhea: evolving concepts in epidemiology and pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18205536" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Postinfectious irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18492522" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Post-infectious functional gastrointestinal disorders in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24173771" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Lactose avoidance for young children with acute diarrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10647976" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Drug-induced diarrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11821511" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical practice. Antibiotic-associated diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30193113" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22570464" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15740542" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31039287" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Probiotics for the prevention of pediatric antibiotic-associated diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35727573" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Multispecies Probiotic for the Prevention of Antibiotic-Associated Diarrhea in Children: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29462280" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28027072" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Spectrum of Drug-induced Chronic Diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29555994" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Extensive impact of non-antibiotic drugs on human gut bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30668547" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Intestinal epithelial potassium channels and CFTR chloride channels activated in ErbB tyrosine kinase inhibitor diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22728033" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Severe spruelike enteropathy associated with olmesartan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28124291" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25557967" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prevalence of functional gastrointestinal disorders in infants and toddlers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27144631" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Childhood Functional Gastrointestinal Disorders: Neonate/Toddler.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27144632" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Functional Disorders: Children and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28167094" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : International consensus guidelines for the diagnosis and management of food protein-induced enterocolitis syndrome: Executive summary-Workgroup Report of the Adverse Reactions to Foods Committee, American Academy of Allergy, Asthma&amp;Immunology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8150360" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Drug induced lymphocytic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29562162" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Autoimmune Polyendocrine Syndromes.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
